Stockreport

 DiaMedica Therapeutics Announces Expansion of DM199 (Rinvecalinase Alfa) Program Into Preeclampsia

DiaMedica Therapeutics Inc.  (DMAC) 
Last diamedica therapeutics inc. earnings: 11/13 04:12 pm Check Earnings Report
PDF  Preeclampsia Program to be Initiated with a Phase 2 Investigator-sponsored Trial Beginning in Q4 2024Key Proof-of-Concept Results Expected in the First Half of 2025Mana [Read more]